Patient P-01403
Therapy response
Improving
Tolerance
Stable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Stable
Discontinuation risk
73%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 52 GI-04 recommended — GI Support Protocol GI-04
- Day 53 Patient accepted — Started GI-04 in the companion
- Day 54 SC-12 recommended — Supportive Compound SC-12
- Day 55 Patient accepted — Started SC-12 in the companion
- Day 61 GI symptom burden −18% vs expected — GI Support Protocol GI-04
- Day 61 GI symptom burden −18% vs expected — Supportive Compound SC-12
- Day 67 Tolerance state changed — Unstable → Improving
- Day 67 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 46.
Primary contributors, last 14 days
- Treatment adherence-11
- Inflammatory activity+8
- GI instability+6
What helped?
- GI Support Protocol GI-04Day 52Result: symptom burden −18%
- Supportive Compound SC-12Day 54Result: symptom burden −18%
LIFE OS recommendation
Dietary Support Protocol NP-02
59%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 46 and rising
- WearableSleep 6.1 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 33/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓40
- Wearable3,641 steps/day
- WearableShort sleep window
- Inflammatory signalling ↑25
- BloodInflammatory load index 55
- Drug metabolism and exposure ↑20
- BloodToxicity index 48
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.5 · butyrate capacity 33/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 54 ms
- Sleep
- 5.7 h
- Steps
- 3,094
- Resting HR
- 64 bpm
Daily log: GI score 46, nutritional resilience 46, adherence 43.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01377 | 22% | S11 | AD-05 | no change | 42 |
| P-01483 | 22% | S14 | AD-05 | no change | 35 |
| P-01689 | 23% | S13 | BR-03 | no change | 50 |
| P-01371 | 30% | S06 | CR-01 | improved | 63 |
| P-01708 | 30% | S07 | CR-01 | improved | 59 |
| P-01696 | 28% | S20 | CR-01 | improved | 59 |
| P-01442 | 27% | S13 | CR-01 | improved | 61 |
| P-01388 | 26% | S17 | CR-01 | improved | 59 |
| P-01835 | 26% | S17 | CR-01 | improved | 56 |
| P-01877 | 24% | S01 | CR-01 | improved | 67 |
| P-01430 | 23% | S05 | CR-01 | improved | 54 |
| P-01767 | 23% | S14 | DT-01 | no change | 63 |